XML 47 R5.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statement of Stockholders' Equity - USD ($)
$ in Thousands
Total
Convertible Preferred Shares
Common Shares
Additional Paid-In Capital
Deficit
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2018   1,164,000 55,518,800      
Beginning balance at Dec. 31, 2018 $ 200,234 $ 126,136 $ 879,405 $ 48,084 $ (805,221) $ (48,170)
Accretion of accumulated dividends on Preferred Shares 0 $ 2,715     (2,715)  
Stock-based compensation 1,665     1,665    
Certain fair value adjustments to liability stock option awards 47     47    
Issuance of common shares pursuant to the Sale Agreement 2,248          
Issuance of common shares (in shares) pursuant to our Open Market Sales Agreement     614,401      
Issuance of common shares pursuant to our Open Market Sales Agreement     $ 2,248      
Issuance of common shares pursuant to exercise of options (in shares)     122,603      
Issuance of common shares pursuant to exercise of options 288   $ 490 (202)    
Unrealized gain on available-for-sale securities (22)         (22)
Net loss (23,251)       (23,251)  
Ending balance (in shares) at Mar. 31, 2019   1,164,000 56,255,804      
Ending balance at Mar. 31, 2019 181,209 $ 128,851 $ 882,143 49,594 (831,187) (48,192)
Beginning balance (in shares) at Dec. 31, 2019   1,164,000 64,780,314      
Beginning balance at Dec. 31, 2019 72,744 $ 137,285 $ 898,535 55,246 (970,093) (48,229)
Accretion of accumulated dividends on Preferred Shares   $ (2,978)     2,978  
Stock-based compensation 1,460     1,460    
Certain fair value adjustments to liability stock option awards 180     180    
Issuance of common shares pursuant to the Sale Agreement 12,315          
Issuance of common shares (in shares) pursuant to our Open Market Sales Agreement     4,147,081      
Issuance of common shares pursuant to our Open Market Sales Agreement     $ 12,315      
Issuance of common shares pursuant to exercise of options (in shares)     34,000      
Issuance of common shares pursuant to exercise of options 166   $ 249 (83)    
Unrealized gain on available-for-sale securities 252         252
Net loss (13,861)       (13,861)  
Ending balance (in shares) at Mar. 31, 2020   1,164,000 68,961,395      
Ending balance at Mar. 31, 2020 $ 73,256 $ 140,263 $ 911,099 $ 56,803 $ (986,932) $ (47,977)